Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
Go back to Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy| (NASDAQ: AKCA) | Delayed: 18.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.17 | 52 Week High | $ | |||
| Open | $22.77 | 52 Week Low | $ | |||
| Day High | $18.17 | P/E | N/A | |||
| Day Low | $18.17 | EPS | $ | |||
| Volume | 2,023 | |||||
| (NASDAQ: IONS) | Delayed: 56.71 -1.38 (2.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.09 | 52 Week High | $62.68 | |||
| Open | $52.15 | 52 Week Low | $19.59 | |||
| Day High | $57.43 | P/E | N/A | |||
| Day Low | $52.15 | EPS | $0.00 | |||
| Volume | 9,175,678 | |||||
